Clinical Trial Update: A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants [Phase 2]

View source ↗

Summary

Phase 2 trial comparing nivolumab plus ipilimumab versus pemetrexed with platinum for unresectable pleural mesothelioma in Chinese participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pleural Mesothelioma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Mesothelioma, Malignant | Phase 2 | Status: COMPLETED